Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Neurology and Neurosurgery
  • Neurology & Neurosurgery News
  • Cinpanemab fails to...

Cinpanemab fails to slow disease progression in patients with early Parkinson's disease: NEJM

Dr. Hiral patelWritten by Dr. Hiral patel Published On 2022-08-04T19:30:16+05:30  |  Updated On 4 Aug 2022 2:00 PM GMT
Cinpanemab fails to slow disease progression in patients with early Parkinsons disease: NEJM

Toronto: In the phase 2 SPARK study trial, cinpanemab did not show any beneficial effect concerning clinical, imaging, or quality-of-life measures as compared to placebo in patients with early Parkinson's disease. The study article was published in the New England Journal of Medicine.Globally, Parkinson's disease is the numerically fastest growing and the second most common...

Toronto: In the phase 2 SPARK study trial, cinpanemab did not show any beneficial effect concerning clinical, imaging, or quality-of-life measures as compared to placebo in patients with early Parkinson's disease. The study article was published in the New England Journal of Medicine.

Globally, Parkinson's disease is the numerically fastest growing and the second most common neurodegenerative disorder. In Parkinson's disease, dopamine replacement has a substantial benefit concerning symptoms, but it does not slow disease progression. Also, there is a risk of developing levodopa-resistant symptoms over time, thus disease-modifying therapies beyond currently existing ones are needed. Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody targeting aggregated α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.

Phase 1 study of Cinpanemab, suggested its dose-dependent biologic activity in persons with Parkinson's disease. Anthony E. Lang, the University of Toronto, Toronto, and his research team conducted a phase 2 trial to assess the clinical effect, safety, pharmacokinetics, and pharmacodynamics of intravenously administered cinpanemab in persons with early-stage Parkinson's disease. Researchers enrolled 357 participants with early Parkinson's disease for the 52-week trial. Participants were randomly assigned in a 2:1:2:2 ratio to receive intravenous infusions of placebo (control, n-100) or cinpanemab at a dose of 250 mg(n-55), 1250 mg(n-102), or 3500 mg(n-100) every 4 weeks, followed by an active-treatment dose-blinded extension period for up to 112 weeks.

The primary endpoints were the changes from baseline in the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score (range, 0 to 236, with higher scores indicating worse performance) at weeks 52 and 72. Secondary endpoints included MDS-UPDRS subscale scores and striatal binding as assessed on dopamine transporter single-photon-emission computed tomography (DaT-SPECT).

Key findings of the trial,

• The change in the MDS-UPDRS score at 52 weeks was 10.8 points in the control group, 10.5 points in the 250-mg group, 11.3 points in the 1250-mg group, and 10.9 points in the 3500-mg group (adjusted mean difference vs. control, −0.3 points P=0.90; 0.5 points, P=0.80; and 0.1 points, P=0.97, respectively).

• The adjusted mean difference at 72 weeks between participants who received cinpanemab through 72 weeks and the pooled group of those who started cinpanemab at 52 weeks was −0.9 points, 0.6 points, and −0.8 points for the dose of 250-mg, 1250-mg and 3500-mg dose, respectively.

• Results for secondary endpoints were similar to those for the primary endpoints.

• DaT-SPECT imaging at week 52 showed no differences between the control group and any cinpanemab group.

• The most common adverse events with cinpanemab were headaches, nasopharyngitis, and falls.

Researchers had to stop the trial after the week 72 interim analysis owing to lack of efficacy.

Researchers conclude that the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over 52 weeks in participants with early Parkinson's disease. Also, the adverse events in cinpanemab-treated participants were mostly mild to moderate in severity.

Reference:

Lang, Anthony E.,Siderowf Andrew D.,Macklin Eric A.,Werner Poewe et al. Trial of Cinpanemab in Early Parkinson's Disease   New England Journal of Medicine  2022. doi: 10.1056/NEJMoa2203395

New England Journal of Medicine cinpanemab Parkinson’s disease 
Source : New England Journal of Medicine
Dr. Hiral patel
Dr. Hiral patel

    BDS

    Dr. Hiral patel (BDS) has completed BDS from Gujarat University, Baroda. She has worked in private dental steup for 8years and is currently a consulting general dentist in mumbai. She has recently completed her advanced PG diploma in clinical research and pharmacovigilance. She is passionate about writing and loves to read, analyses and write informative medical content for readers. She can be contacted at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X